| Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis P Savas, B Virassamy, C Ye, A Salim, CP Mintoff, F Caramia, R Salgado, ... Nature medicine 24 (7), 986-993, 2018 | 929 | 2018 |
| CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity ML Burr, CE Sparbier, YC Chan, JC Williamson, K Woods, PA Beavis, ... Nature 549 (7670), 101-105, 2017 | 827 | 2017 |
| Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells LB John, C Devaud, CPM Duong, CS Yong, PA Beavis, NM Haynes, ... Clinical cancer research 19 (20), 5636-5646, 2013 | 812 | 2013 |
| CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer S Loi, S Pommey, B Haibe-Kains, PA Beavis, PK Darcy, MJ Smyth, ... Proceedings of the National Academy of Sciences 110 (27), 11091-11096, 2013 | 558 | 2013 |
| RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune … S Loi, S Dushyanthen, PA Beavis, R Salgado, C Denkert, P Savas, ... Clinical Cancer Research 22 (6), 1499-1509, 2016 | 555 | 2016 |
| An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer ML Burr, CE Sparbier, KL Chan, YC Chan, A Kersbergen, EYN Lam, ... Cancer cell 36 (4), 385-401. e8, 2019 | 541 | 2019 |
| Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade IG House, P Savas, J Lai, AXY Chen, AJ Oliver, ZL Teo, KL Todd, ... Clinical Cancer Research 26 (2), 487-504, 2020 | 526 | 2020 |
| CD73: a potent suppressor of antitumor immune responses PA Beavis, J Stagg, PK Darcy, MJ Smyth Trends in immunology 33 (5), 231-237, 2012 | 444 | 2012 |
| Targeting the epigenetic regulation of antitumour immunity SJ Hogg, PA Beavis, MA Dawson, RW Johnstone Nature reviews Drug discovery 19 (11), 776-800, 2020 | 437 | 2020 |
| Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors PA Beavis, U Divisekera, C Paget, MT Chow, LB John, C Devaud, ... Proceedings of the National Academy of Sciences 110 (36), 14711-14716, 2013 | 384 | 2013 |
| Tumor immune evasion arises through loss of TNF sensitivity CJ Kearney, SJ Vervoort, SJ Hogg, KM Ramsbottom, AJ Freeman, ... Science immunology 3 (23), eaar3451, 2018 | 336 | 2018 |
| Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity AJ Davenport, RS Cross, KA Watson, Y Liao, W Shi, HM Prince, ... Proceedings of the National Academy of Sciences 115 (9), E2068-E2076, 2018 | 329 | 2018 |
| Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy PA Beavis, MA Henderson, L Giuffrida, JK Mills, K Sek, RS Cross, ... The Journal of clinical investigation 127 (3), 929-941, 2017 | 319 | 2017 |
| Immunosuppressive activities of adenosine in cancer B Allard, PA Beavis, PK Darcy, J Stagg Current opinion in pharmacology 29, 7-16, 2016 | 319 | 2016 |
| Adenosine receptor 2A blockade increases the efficacy of anti–PD-1 through enhanced antitumor T-cell responses PA Beavis, N Milenkovski, MA Henderson, LB John, B Allard, S Loi, ... Cancer immunology research 3 (5), 506-517, 2015 | 317 | 2015 |
| BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1 SJ Hogg, SJ Vervoort, S Deswal, CJ Ott, J Li, LA Cluse, PA Beavis, ... Cell reports 18 (9), 2162-2174, 2017 | 292 | 2017 |
| Intratumoral copper modulates PD-L1 expression and influences tumor immune evasion F Voli, E Valli, L Lerra, K Kimpton, F Saletta, FM Giorgi, D Mercatelli, ... Cancer research 80 (19), 4129-4144, 2020 | 283 | 2020 |
| Relevance of tumor-infiltrating lymphocytes in breast cancer S Dushyanthen, PA Beavis, P Savas, ZL Teo, C Zhou, M Mansour, ... BMC medicine 13, 1-13, 2015 | 272 | 2015 |
| Tissue-resident memory T cells in breast cancer control and immunotherapy responses A Byrne, P Savas, S Sant, R Li, B Virassamy, SJ Luen, PA Beavis, ... Nature Reviews Clinical Oncology 17 (6), 341-348, 2020 | 244 | 2020 |
| CD73-deficient mice are resistant to carcinogenesis J Stagg, PA Beavis, U Divisekera, MCP Liu, A Möller, PK Darcy, MJ Smyth Cancer research 72 (9), 2190-2196, 2012 | 241 | 2012 |
Joseph A TrapaniPeter MacCallum Cancer Centre, Melbourne AustraliaE-mailová adresa ověřena na: petermac.org